Showing results (101-110 of 160) with videos related to
Sort By:
Pageof 16
Cancer Research|May 29, 2015
Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast CancerLina S Schneider, Karin von Schwarzenberg, Thorsten Lehr, et al.Nanomaterials (Basel, Switzerland)|June 2, 2021
Influence of Physicochemical Characteristics and Stability of Gold and Silver Nanoparticles on Biological Effects and Translocation across an Intestinal Barrier-A Case Study from In Vitro to In SilicoYvonne Kohl, Michelle Hesler, Roland Drexel, et al.Scientific Reports|October 24, 2023
Population pharmacokinetic modeling of multiple-dose intravenous fosfomycin in critically ill patients during continuous venovenous hemodialysisTobias Hüppe, Katharina M Götz, Andreas Meiser, et al.Pharmaceutical Research|September 14, 2004
Population dose-response model for tadalafil in the treatment of male erectile dysfunctionAlexander Staab, Christiane Tillmann, S Thomas Forgue, et al.Journal of Clinical Pharmacology|August 14, 2013
Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetesMatthew M Riggs, Alexander Staab, Leo Seman, et al.Journal of Hepatology|May 2, 2016
First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex BAntje Blank, Christoph Markert, Nicolas Hohmann, et al.Scientific Reports|October 9, 2025
Modeling of lung-liver interaction during infection in a human fluidic organ-on-a-chipSusanne Reinhold, Christian Herr, Yiwen Yao, et al.Journal of the American College of Cardiology|October 1, 2013
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)Paul A Reilly, Thorsten Lehr, Sebastian Haertter, et al.Clinical Pharmacokinetics|November 9, 2010
Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjectsSilke Retlich, Vincent Duval, Arne Ring, et al.International Journal of Oncology|March 3, 2007
Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neckAlexander Sauter, Charlotte Kloft, Silke Gronau, et al.Pageof 16